CL2020001139A1 - Derivados de sulfonamida aromáticos para el tratamiento de accidente cere-brovascular isquémico. - Google Patents

Derivados de sulfonamida aromáticos para el tratamiento de accidente cere-brovascular isquémico.

Info

Publication number
CL2020001139A1
CL2020001139A1 CL2020001139A CL2020001139A CL2020001139A1 CL 2020001139 A1 CL2020001139 A1 CL 2020001139A1 CL 2020001139 A CL2020001139 A CL 2020001139A CL 2020001139 A CL2020001139 A CL 2020001139A CL 2020001139 A1 CL2020001139 A1 CL 2020001139A1
Authority
CL
Chile
Prior art keywords
treatment
ischemic stroke
sulfonamide derivatives
aromatic sulfonamide
ischemic
Prior art date
Application number
CL2020001139A
Other languages
English (en)
Inventor
Stefan Werner
Peter Hauff
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CL2020001139A1 publication Critical patent/CL2020001139A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN COMPUESTO DE LA FÓRMULA (I) (I) O UN N–ÓXIDO, UNA SAL, UN HIDRATO, UN SOLVATO, UN TAUTÓMERO O UN ESTEREOISÓMERO DE DICHO COMPUESTO, O UNA SAL DE DICHO N ÓXIDO, TAUTÓMERO O ESTEREOISÓMERO PARA USO EN EL TRATAMIENTO O LA PREVENCIÓN DE ISQUEMIA CEREBRAL, LESIÓN CEREBRAL ISQUÉMICA, ACCIDENTE CEREBROVASCULAR ISQUÉMICO (IS), ACCIDENTE CEREBROVASCULAR HEMORRÁGICO, LESIÓN CEREBRAL TRAUMÁTICA, LESIÓN DE LA MÉDULA ESPINAL.
CL2020001139A 2017-10-29 2020-04-29 Derivados de sulfonamida aromáticos para el tratamiento de accidente cere-brovascular isquémico. CL2020001139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17199070 2017-10-29

Publications (1)

Publication Number Publication Date
CL2020001139A1 true CL2020001139A1 (es) 2020-10-23

Family

ID=60191221

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001139A CL2020001139A1 (es) 2017-10-29 2020-04-29 Derivados de sulfonamida aromáticos para el tratamiento de accidente cere-brovascular isquémico.

Country Status (16)

Country Link
US (1) US20210179577A1 (es)
EP (1) EP3700891A1 (es)
JP (1) JP2021501178A (es)
KR (1) KR20200081445A (es)
CN (1) CN111511720A (es)
AU (1) AU2018356430A1 (es)
BR (1) BR112020008484A2 (es)
CA (1) CA3079469A1 (es)
CL (1) CL2020001139A1 (es)
EA (1) EA202091028A1 (es)
IL (1) IL274041A (es)
JO (1) JOP20200077A1 (es)
MA (1) MA50448A (es)
MX (1) MX2020004472A (es)
SG (1) SG11202003565PA (es)
WO (1) WO2019081573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809126RA (en) * 2016-05-03 2018-11-29 Bayer Pharma AG Aromatic sulfonamide derivatives
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2022002859A1 (en) 2020-06-30 2022-01-06 Bayer Aktiengesellschaft Substituted n-phenylacetamides having p2x4 receptor antagonistic activity
WO2022049253A1 (en) 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
WO2022161416A1 (zh) * 2021-01-27 2022-08-04 武汉朗来科技发展有限公司 一种芳香化合物、其制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ES2609335T3 (es) * 2009-09-03 2017-04-19 Bristol-Myers Squibb Company Quinazolinas como inhibidores de los canales iónicos de potasio
JP2013523658A (ja) 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのピラゾリル‐ピリミジン
CA2798080C (en) 2010-05-17 2020-08-25 Incozen Therapeutics Pvt. Ltd. 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2015088564A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds
WO2015088565A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds and methods of use thereof
EP3307715A1 (en) * 2015-06-10 2018-04-18 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
SG11201809126RA (en) * 2016-05-03 2018-11-29 Bayer Pharma AG Aromatic sulfonamide derivatives

Also Published As

Publication number Publication date
EP3700891A1 (en) 2020-09-02
KR20200081445A (ko) 2020-07-07
MX2020004472A (es) 2020-08-06
IL274041A (en) 2020-06-30
US20210179577A1 (en) 2021-06-17
WO2019081573A1 (en) 2019-05-02
WO2019081573A9 (en) 2020-05-28
BR112020008484A2 (pt) 2020-10-20
JOP20200077A1 (ar) 2020-04-30
AU2018356430A1 (en) 2020-04-30
CN111511720A (zh) 2020-08-07
EA202091028A1 (ru) 2020-09-09
MA50448A (fr) 2020-09-02
CA3079469A1 (en) 2019-05-02
JP2021501178A (ja) 2021-01-14
SG11202003565PA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CL2020001139A1 (es) Derivados de sulfonamida aromáticos para el tratamiento de accidente cere-brovascular isquémico.
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP18082774A (es) Derivados aromáticos de sulfonamida
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2015002814A1 (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
CL2012003540A1 (es) Compuestos derivados de triazolopiridinas sustituidas; metodo de preparacion; compuestos intermediarios; composicion farmaceutica que los comprende; uso del compuesto para la profilaxis o el tratamiento de leucemia, linfomas malignos, tumores de cabeza y cuello, tumores del torax, tumores gastrointestinales, entre otros.
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2017000792A1 (es) Derivados del ácido borónico
CR20170315A (es) Inhibridores bace 1 selectivos
EA201791304A1 (ru) Производные изохинолина для лечения вич
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
MX2019006697A (es) Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
SV2018005713A (es) Compuestos de isoindol
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
AU2017268006A8 (en) Benzenesulfonamide compounds and their use as therapeutic agents
AR111665A1 (es) Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp
WO2015111085A8 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
CL2017000644A1 (es) Compuestos esteroides c-20, composiciones y usos de estos para tratar lesiones cerebrales traumáticas (tbi), incluidas concusiones.
WO2015106242A3 (en) Bisamide compounds as allosteric effectors for reducing the oxygen-binding affinity of hemoglobin
BR112018015855A2 (pt) derivado de sulfonamida.